Eli Lilly and Novo Nordisk Reach Landmark Deal to Slash Obesity Drug Prices
Eli Lilly and Novo Nordisk have reached an agreement with the Trump administration to significantly reduce prices of their weight-loss drugs in exchange for tariff relief and expanded Medicare access. The deal includes a 3-year grace period from duties on pharmaceutical imports and sets Medicare pricing at $245 monthly with a $50 co-pay starting next year. The agreement expands Medicare coverage to overweight individuals with prediabetes, potentially adding 40 million eligible patients. Both companies will receive fast-track regulatory reviews for new products. Eli Lilly's weight-loss pill, orforglipron, could be approved by March at a projected price of $149 monthly for the lowest dose.
*this image is generated using AI for illustrative purposes only.
Eli Lilly and Company, along with its competitor Novo Nordisk, have struck a significant agreement with the Trump administration, promising to substantially reduce the prices of their popular weight-loss drugs in exchange for tariff relief and expanded Medicare access. This deal marks a pivotal moment in the accessibility of these increasingly sought-after medications.
Key Points of the Agreement
| Aspect | Details |
|---|---|
| Tariff Relief | 3-year grace period from duties on pharmaceutical imports |
| Medicare Price | $245.00 monthly with a $50.00 co-pay (starting next year) |
| Current US List Price | Exceeding $1,000.00 monthly |
| Lilly's Direct Offer | $50.00 less than current pricing through LillyDirect |
| Novo's Offer | $499.00 monthly via NovoCare for Wegovy |
Expanded Medicare Coverage
The agreement significantly broadens the scope of Medicare coverage for these weight-loss drugs. Previously limited to individuals with obesity and additional conditions like heart disease, the new terms will extend coverage to overweight individuals with prediabetes. This expansion could potentially add 40 million eligible patients to the current 8-9 million Americans using these GLP-1 drugs.
Fast-Track Reviews
As part of the deal, both companies are set to benefit from expedited regulatory reviews:
Eli Lilly received fast-track review for its weight-loss pill, orforglipron
- Potential approval time reduced to weeks
- Possible March clearance
- Projected price: $149.00 monthly for the lowest dose
Novo Nordisk will get expedited review for a higher-dose injection
Market Impact
This agreement is poised to reshape the landscape of obesity treatment in the United States. By dramatically reducing the cost barrier and expanding insurance coverage, these highly effective weight-loss medications may become accessible to a much broader population. The deal also highlights the intersection of healthcare policy, pharmaceutical pricing, and government negotiations in addressing public health concerns.
As the obesity epidemic continues to be a significant health issue in the United States, this agreement could potentially lead to improved health outcomes for millions of Americans. However, the long-term economic and health impacts of such widespread access to these medications remain to be seen.
The move also underscores the ongoing debate about drug pricing in the United States and the role of government intervention in healthcare markets. As this agreement takes effect, it will be crucial to monitor its impact on patient access, healthcare costs, and the broader pharmaceutical industry.
19
